Key Highlights:
- Sun Pharmaceutical announced that the Drugs Controller General of India has approved its generic version of Semaglutide injection for chronic weight management in adults, to be used alongside reduced calorie intake and increased physical activity.
- The company plans to launch the product under the brand name Noveltreat after the patent expiry in India. The once-weekly therapy will be available in five dose strengths and delivered through a prefilled pen designed for convenient and accurate dosing.
- The approval follows a Phase III clinical trial conducted in India and expands Sun Pharma’s GLP-1 portfolio. Earlier, the company also received DCGI approval for semaglutide for treating Type 2 Diabetes, which it plans to launch under the brand name Sematrinity after the patent expiry.
Implications:
Sun ignites generics price war against Novo/Eli Lilly premium brands, slashing obesity therapy costs and exploding Tier-2/3 access.
Dual T2D/weight loss launches position Sun as GLP-1 kingmaker, crushing smaller players while stealing endocrinologist prescriptions.
Source: Expresspharma | Image: Sun pharmaceutical
